Early-Stage Investments Propel Jump In Life Sciences Venture Capital
This article was originally published in The Tan Sheet
In some cases, early venture capital appears to be substituting for the public market in providing finance not only to start but also sustain companies in specialty pharma and in-licensing, development-only businesses. At least 200 capital groups took part in the 156 recorded A rounds, and 50 participated in more than one.
Register for our free email digests: